Literature DB >> 30858987

A guide to the reporting of protocols of pilot and feasibility trials.

Lehana Thabane1, Gillian Lancaster2.   

Abstract

Publishing protocols of trials including protocols of pilot and feasibility trials-designed to inform the designs of main trials-has been advocated as an important strategy towards improving transparency in the conduct and reporting of main trials and pilot/feasibility trials. This editorial aims to provide some general guidance on how to report protocols of pilot and feasibility trials, drawing upon two available resources-the CONSORT extension to pilot trials and the SPIRIT guideline for main trials. We describe how these might be adapted for the reporting of protocol manuscripts of pilot and feasibility trials for submission in Pilot and Feasibility Studies journal.

Entities:  

Year:  2019        PMID: 30858987      PMCID: PMC6393983          DOI: 10.1186/s40814-019-0423-8

Source DB:  PubMed          Journal:  Pilot Feasibility Stud        ISSN: 2055-5784


Introduction

The journal Pilot and Feasibility Studies (PFS) was launched in 2015 to provide a forum for publishing pilot and feasibility research. PFS’s scope “encompasses all aspects of the design, conduct and reporting of pilot and feasibility studies in biomedicine. The journal publishes research articles that are intended to directly influence future clinical trials or large-scale observational studies, as well as protocols….” [1]. First published in 1996 [2] and updated in 2010 [3], the CONSORT Statement was developed to improve the transparency of the reporting of randomised controlled trials (RCTs). CONSORT was then extended to cover various types of study outcomes [4, 5], RCT designs [6-9], and types of interventions [10-12]. In 2016, we developed the CONSORT extension to pilot trials to help researchers who conduct pilot and feasibility trials to report them in a way that allows readers to understand what had been done, what the results were, and how to interpret them [13-15]. For the results of pilot and feasibility trials, PFS now requires that submissions include the checklist from the CONSORT extension to pilot trials [1]. Publishing protocols of trials has been advocated as an important strategy towards improving transparency in the conduct and reporting of trials [16, 17]. This has allowed investigators to assess consistency between protocols and final reports of trials [18], as a way to hold authors more accountable and to help readers to better assess the validity of the final trial results. Most importantly, it has helped readers to better understand the conduct and applicability of the trial and better apply the results to patient care. Today, publication of trial protocols in scientific journals has become more commonplace. The SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guideline was published in 2013. It aims to improve the completeness and quality of reporting clinical trial protocols [19]. SPIRIT defines a protocol as “a document that provides sufficient detail to enable understanding of the background, rationale, objectives, study population, interventions, methods, statistical analyses, ethical considerations, dissemination plans, and administration of the trial; replication of key aspects of trial methods and conduct; and appraisal of the trial’s scientific and ethical rigour from ethics approval to dissemination of results” [19]. The guideline includes a full statement, a checklist of items that should be included in a trial protocol publication, and a detailed explanation of the importance of each item, with examples of best practices [20]. Reporting guidelines such as SPIRIT have several potential benefits to various stakeholders [21]: (1) for funding agencies—to use guideline items as part of a grant submission template and evaluation criteria (e.g. Swiss National Science Foundation [http://www.snf.ch/SiteCollectionDocuments/IICT_2018_Proposal_Template.docx, http://www.snf.ch/en/funding/programmes/iict/Pages/default.aspx#Documents] and National Health and Medical Research Council [https://www.australianclinicaltrials.gov.au/clinical-trials-toolkit]); (ii) for authors—to use the guideline checklist as a template when preparing trial manuscripts for publication; (iii) for peer-reviewers of journal manuscripts—to endorse the guideline in their instructions to authors and to require the guideline checklist to be included as part of their submission process (e.g. Trials [https://trialsjournal.biomedcentral.com/]) and BMJ Open [https://bmjopen.bmj.com/]); and (iv) for higher education institutions—to endorse guidelines and ensure that they are incorporated into their institutional research publication policies (see http://www.spirit-statement.org/about-spirit/spirit-endorsement/). The absence of reporting guidelines can be a serious barrier to the full and transparent dissemination of knowledge through scientific research—reflecting poorly on all stakeholders and potentially leading to biased reporting, waste of resources, and unusable research that is hard or impossible to replicate. Against this backdrop, a call for publication of protocol guidance for pilot and feasibility studies was made in 2016 [22]. While this work has been planned by the same working group that developed the CONSORT extension to pilot trials, which includes ourselves, we recognise that some guidance from the journal editors would be helpful. This editorial aims to provide some general guidance in the interim, drawing upon two sources—the CONSORT extension to pilot trials and the SPIRIT guideline for main trials. We describe how these might be adapted for the reporting of protocols of pilot and feasibility trials.

Guidance for writing protocols of pilot and feasibility trials for submission to PFS journal

Since its inception in 2015, the PFS journal has routinely published articles reporting protocols for pilot and feasibility studies. PFS’s policy is that protocol manuscripts should be submitted to the journal before the recruitment and follow-up of study participants have been completed. To date, there is no specific evidence-based guidance describing the items that should be included when reporting the protocol for a pilot and feasibility trial. We suggest that it is helpful to refer to the CONSORT extension to pilot trials for more elaboration on items to report at the start of the work when planning the study protocol, while concurrently adapting the SPIRIT checklist for reporting the protocol of a pilot trial. However, SPIRIT is designed to comprehensively report main trials of effectiveness. This is not the primary aim of a pilot trial, which aims to test a set of feasibility objectives to ensure the main trial is viable. We suggest adapting SPIRIT for manuscripts that report the protocols of pilot and feasibility trials. The SPIRIT checklist can be found on the SPIRIT Statement website at http://www.spirit-statement.org/. For example, all Background elements of the SPIRIT guideline would be suitable to consider in the Background section of the protocol for a pilot trial, supplemented by the item from the CONSORT extension (item 2a) that specifies the reason for the pilot trial set in the context of the main trial. The CONSORT extension to pilot trials (item 2b) also stresses the importance of giving clear aims and feasibility objectives for the pilot trial at the end of the introduction. These would provide the main focus of the pilot trial protocol (replacing SPIRIT item 7). In the Methods section, rather than describing the primary and secondary outcome measures as stipulated in SPIRIT (item 12), we should instead describe the methods for the primary and secondary feasibility outcomes, for example recruitment rate, compliance in data collection or acceptability of the intervention to patients and health practitioners, or secondary patient-centred outcome measures to be used for data collection (CONSORT extension item 6a). Similar adaptations should be made for SPIRIT item 14 (CONSORT item 7a) on sample size and SPIRIT item 20a (CONSORT item 12a) on data analysis. Thus, one can consider the SPIRIT elements in the context of assessment of feasibility as the primary aim for a pilot trial and therefore adapt them appropriately, supplemented with reference to the CONSORT extension explanations. It is important to note that all elements of the Background and Methods are generally part of the design of a trial, and therefore, they would typically be addressed in the protocol of the pilot trial, which is addressing any uncertainties in study design. Headway has been made into producing a guideline for reporting pilot trial protocols. The next step of the working group is to convene a consensus meeting to discuss the suggested adaptations with the aim of producing a final checklist that can be used to write the statement and explanatory paper for the SPIRIT extension to protocols of pilot and feasibility studies. In the meantime, we hope the suggested adaptations will be useful to authors in reporting protocols of pilot and feasibility studies submitted to PFS.
  19 in total

1.  Better reporting of harms in randomized trials: an extension of the CONSORT statement.

Authors:  John P A Ioannidis; Stephen J W Evans; Peter C Gøtzsche; Robert T O'Neill; Douglas G Altman; Kenneth Schulz; David Moher
Journal:  Ann Intern Med       Date:  2004-11-16       Impact factor: 25.391

2.  Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement.

Authors:  Joel J Gagnier; Heather Boon; Paula Rochon; David Moher; Joanne Barnes; Claire Bombardier
Journal:  Ann Intern Med       Date:  2006-03-07       Impact factor: 25.391

3.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

4.  Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments.

Authors:  Isabelle Boutron; David Moher; Douglas G Altman; Kenneth F Schulz; Philippe Ravaud
Journal:  Ann Intern Med       Date:  2008-02-19       Impact factor: 25.391

5.  Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement.

Authors:  Hugh MacPherson; Douglas G Altman; Richard Hammerschlag; Li Youping; Wu Taixiang; Adrian White; David Moher
Journal:  PLoS Med       Date:  2010-06-08       Impact factor: 11.069

6.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

Authors:  Kenneth F Schulz; Douglas G Altman; David Moher
Journal:  BMJ       Date:  2010-03-23

7.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.

Authors:  Gilda Piaggio; Diana R Elbourne; Stuart J Pocock; Stephen J W Evans; Douglas G Altman
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

8.  SPIRIT 2013 statement: defining standard protocol items for clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Douglas G Altman; Andreas Laupacis; Peter C Gøtzsche; Karmela Krleža-Jerić; Asbjørn Hróbjartsson; Howard Mann; Kay Dickersin; Jesse A Berlin; Caroline J Doré; Wendy R Parulekar; William S M Summerskill; Trish Groves; Kenneth F Schulz; Harold C Sox; Frank W Rockhold; Drummond Rennie; David Moher
Journal:  Ann Intern Med       Date:  2013-02-05       Impact factor: 25.391

9.  Consort 2010 statement: extension to cluster randomised trials.

Authors:  Marion K Campbell; Gilda Piaggio; Diana R Elbourne; Douglas G Altman
Journal:  BMJ       Date:  2012-09-04

10.  Improving the reporting of pragmatic trials: an extension of the CONSORT statement.

Authors:  Merrick Zwarenstein; Shaun Treweek; Joel J Gagnier; Douglas G Altman; Sean Tunis; Brian Haynes; Andrew D Oxman; David Moher
Journal:  BMJ       Date:  2008-11-11
View more
  33 in total

Review 1.  Developing and Evaluating Behaviour Change Interventions for People with Younger-Onset Type 2 Diabetes: Lessons and Recommendations from Existing Programmes.

Authors:  Amelia J Lake; Anne Bo; Michelle Hadjiconstantinou
Journal:  Curr Diab Rep       Date:  2021-12-13       Impact factor: 4.810

2.  Guidelines for Designing and Evaluating Feasibility Pilot Studies.

Authors:  Jeanne A Teresi; Xiaoying Yu; Anita L Stewart; Ron D Hays
Journal:  Med Care       Date:  2022-01-01       Impact factor: 2.983

3.  Evaluating the Public Climate School-A School-Based Programme to Promote Climate Awareness and Action in Students: Protocol of a Cluster-Controlled Pilot Study.

Authors:  Michael Eichinger; Myriam Bechtoldt; Inga Thao My Bui; Julius Grund; Jan Keller; Ashley G Lau; Shuyan Liu; Michael Neuber; Felix Peter; Carina Pohle; Gerhard Reese; Fabian Schäfer; Stephan Heinzel
Journal:  Int J Environ Res Public Health       Date:  2022-06-30       Impact factor: 4.614

4.  A mixed-methods feasibility study of a comorbidity-adapted exercise program for low back pain in older adults (COMEBACK): a protocol.

Authors:  Katie de Luca; Megan Yanz; Aron Downie; Julie Kendall; Søren T Skou; Jan Hartvigsen; Simon D French; Manuela L Ferreira; Sita M A Bierma-Zeinstra
Journal:  Pilot Feasibility Stud       Date:  2022-07-02

5.  A feasibility study on yoga's mechanism of action for chronic low back pain: psychological and neurophysiological changes, including global gene expression and DNA methylation, following a yoga intervention for chronic low back pain.

Authors:  Bandita Adhikari; Angela Starkweather; Wanli Xu; Rebecca L Acabchuk; Divya Ramesh; Bright Eze; Yuxuan Yang; Gee Su Yang; Joseph Walker; Reinhard Laubenbacher; Crystal L Park
Journal:  Pilot Feasibility Stud       Date:  2022-07-07

6.  Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial.

Authors:  Deonna M Ackermann; Mbathio Dieng; Ellie Medcalf; Marisa C Jenkins; Cathelijne H van Kemenade; Monika Janda; Robin M Turner; Anne E Cust; Rachael L Morton; Les Irwig; Pascale Guitera; H Peter Soyer; Victoria Mar; Jolyn K Hersch; Donald Low; Cynthia Low; Robyn P M Saw; Richard A Scolyer; Dorothy Drabarek; David Espinoza; Anthony Azzi; Alister M Lilleyman; Amelia K Smit; Peter Murchie; John F Thompson; Katy J L Bell
Journal:  JAMA Dermatol       Date:  2022-01-01       Impact factor: 11.816

7.  Contextual interference in children with brain lesions: protocol of a pilot study investigating blocked vs. random practice order of an upper limb robotic exergame.

Authors:  Judith V Graser; Caroline H G Bastiaenen; Urs Keller; Hubertus J A van Hedel
Journal:  Pilot Feasibility Stud       Date:  2020-10-15

8.  The Effects of Home Exercise in Older Women With Vertebral Fractures: A Pilot Randomized Controlled Trial.

Authors:  Jenna C Gibbs; Caitlin McArthur; John D Wark; Lehana Thabane; Samuel C Scherer; Sadhana Prasad; Alexandra Papaioannou; Nicole Mittmann; Judi Laprade; Sandra Kim; Aliya Khan; David L Kendler; Keith D Hill; Angela M Cheung; Robert Bleakney; Maureen C Ashe; Jonathan D Adachi; Lora M Giangregorio
Journal:  Phys Ther       Date:  2020-04-17

9.  Early clinical management of severe burn patients using telemedicine: a pilot study protocol.

Authors:  Maxim Moreau; Guy Paré
Journal:  Pilot Feasibility Stud       Date:  2020-07-04

10.  Guidelines for reporting non-randomised pilot and feasibility studies.

Authors:  Gillian A Lancaster; Lehana Thabane
Journal:  Pilot Feasibility Stud       Date:  2019-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.